TXG News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TX

Mkt Cap

$9.10B

Volume

2.79M

Next Earnings

November 5th

Loading chart

TX

TXG10x Genomics, Inc. Class A Common Stock

TXG

Pay with—

Available Balance0.00

TX

Mkt Cap

$9.10B

Volume

2.79M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date.Zacks Investment Research · Oct 8, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and AutomationThe global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.GlobeNewswire Inc. · Oct 6, 2026

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises10x Genomics has begun commercial shipments of Atera, its next-generation spatial biology platform, with booked orders exceeding 40 instruments and demand surpassing initial 2026 expectations. The platform enables whole-transcriptome analysis with single-cell sensitivity and is gaining traction across academic, translational, and biopharma research. The global spatial transcriptomics market is projected to reach $495.2 million by 2026 with a 14.7% CAGR through 2033.Zacks Investment Research · Sep 30, 2026

Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?Hims & Hers Health (HIMS) stock has declined 7.7% since its Q2 2026 earnings report. While the company beat revenue expectations with $753.2M (up 38.2% YoY) and raised full-year guidance to $3.1-3.3B, it missed on earnings with an adjusted loss of 10 cents per share versus consensus of 7 cents. Gross margins contracted significantly by 1,256 basis points to 63.8%, and operating expenses surged 48.4% YoY. Analyst estimates have shifted downward 27.35% since the report, and the stock carries a Zacks Rank #3 (Hold) with a VGM Score of D.Zacks Investment Research · Sep 9, 2026

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences10x Genomics secured a favorable jury verdict against Parse Biosciences (a Qiagen subsidiary), winning $4.8M in damages for willful patent infringement on three single-cell analysis patents. The jury upheld all three patents' validity. 10x Genomics plans to seek enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings. Despite the legal win, TXG shares fell over 5% following the announcement.Zacks Investment Research · Aug 31, 2026

State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health AdoptionBCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.GlobeNewswire Inc. · Aug 25, 2026

Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with ConfidenceResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.GlobeNewswire Inc. · Aug 7, 2026

Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ DealsResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.GlobeNewswire Inc. · Jul 17, 2026

Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS InsiderThe global spatial genomics and transcriptomics market is projected to grow from USD 0.60 billion in 2025 to USD 1.90 billion by 2035 at a 12.23% CAGR. Growth is driven by increased adoption of AI-powered spatial biology technologies, precision medicine initiatives, and high-resolution molecular profiling in oncology and translational research. North America is expected to lead with 46% market share, while Asia Pacific shows the highest growth rate at 16.69% CAGR.GlobeNewswire Inc. · Jun 30, 2026

This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%Quantedge Capital added 212,600 shares of 10x Genomics in Q1 2026 for approximately $4.25 million, signaling investor confidence in the company. The stock has surged 116% over the past year, significantly outperforming the S&P 500's 26% gain. Despite being unprofitable, 10x Genomics showed improving fundamentals with 9% adjusted revenue growth, 70% gross margins, and the launch of Atera, a significant new spatial biology platform.The Motley Fool · May 12, 2026

to start trading

TX

TXG10x Genomics, Inc. Class A Common Stock

TXG

Pay with—

Available Balance0.00

Your PositionYou don't own any TXG yet.

Related Tickers

Earnings